Discovery of a new chemical scaffold for the treatment of superbug Candida auris infections

ABSTRACT Candida auris has emerged as a serious threat of public health and caused global epidemic due to multi-drug resistance, remarkable transmissibility and high mortality. To tackle the challenging super fungus, novel benzoanilide antifungal agents were discovered by an integrated strategy of phenotypic screen, hit optimization, antifungal assays and mechanism exploration. The most promising compound A1 showed potent in vitro and in vivo efficacy against Candida auris infection. Mechanism investigation revealed that compound A1 blocked the biosynthesis of virulence factors and fungal cell walls through the inhibition of glycosylphosphatidylinositol (GPI) and GPI-anchored proteins. Thus, compound A1 represents a promising lead compound to combat drug-resistant candidiasis.

[1]  C. Sheng,et al.  Small molecules for combating multidrug-resistant superbug Candida auris infections , 2022, Acta pharmaceutica Sinica. B.

[2]  Guanghua Huang,et al.  Innate immune responses against the fungal pathogen Candida auris , 2022, Nature Communications.

[3]  C. Rodríguez-Cerdeira,et al.  Epidemiology of Systemic Mycoses in the COVID-19 Pandemic , 2021, Journal of fungi.

[4]  M. Bassetti,et al.  Recent advances and future perspectives in the pharmacological treatment of Candida auris infections , 2021, Expert review of clinical pharmacology.

[5]  G. Vediyappan,et al.  Cell Surface Expression of Nrg1 Protein in Candida auris , 2021, Journal of fungi.

[6]  M. Billamboz,et al.  Promising Drug Candidates and New Strategies for Fighting against the Emerging Superbug Candida auris , 2021, Microorganisms.

[7]  Jian Li,et al.  Discovery of Piperidol Derivatives for Combinational Treatment of Azole-Resistant Candidiasis. , 2021, ACS infectious diseases.

[8]  M. Del Poeta,et al.  Identification of Antifungal Compounds against Multidrug-Resistant Candida auris Utilizing a High-Throughput Drug-Repurposing Screen , 2021, Antimicrobial Agents and Chemotherapy.

[9]  A. Lorenz,et al.  What do we know about the biology of the emerging fungal pathogen of humans Candida auris? , 2020, Microbiological research.

[10]  Guanghua Huang,et al.  Candida auris: Epidemiology, biology, antifungal resistance, and virulence , 2020, PLoS pathogens.

[11]  M. Ghannoum,et al.  Efficacy of Ibrexafungerp (SCY-078) against Candida auris in an In Vivo Guinea Pig Cutaneous Infection Model , 2020, Antimicrobial Agents and Chemotherapy.

[12]  L. Cowen,et al.  Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond. , 2020, Chemical reviews.

[13]  M. Fisher,et al.  Global epidemiology of emerging Candida auris. , 2019, Current opinion in microbiology.

[14]  G. Catano,et al.  Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis , 2019, Antimicrobial Agents and Chemotherapy.

[15]  J. Esteban,et al.  Candida auris: a comparison between planktonic and biofilm susceptibility to antifungal drugs. , 2019, Journal of medical microbiology.

[16]  J. Pemán,et al.  Identification of Off-Patent Compounds That Present Antifungal Activity Against the Emerging Fungal Pathogen Candida auris , 2019, Front. Cell. Infect. Microbiol..

[17]  Ronald N. Jones,et al.  Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016 , 2019, Open forum infectious diseases.

[18]  C. Sheng,et al.  Discovery of Carboline Derivatives as Potent Antifungal Agents for the Treatment of Cryptococcal Meningitis. , 2019, Journal of medicinal chemistry.

[19]  L. Cowen,et al.  Antifungal drug resistance: evolution, mechanisms and impact. , 2018, Current opinion in microbiology.

[20]  J. Lopez-Ribot,et al.  Screening a Repurposing Library for Inhibitors of Multidrug-Resistant Candida auris Identifies Ebselen as a Repositionable Candidate for Antifungal Drug Development , 2018, Antimicrobial Agents and Chemotherapy.

[21]  M. Fisher,et al.  Worldwide emergence of resistance to antifungal drugs challenges human health and food security , 2018, Science.

[22]  J. Osei Sekyere,et al.  Candida auris: A systematic review and meta‐analysis of current updates on an emerging multidrug‐resistant pathogen , 2018, MicrobiologyOpen.

[23]  Guoqiang Dong,et al.  Emerging New Targets for the Treatment of Resistant Fungal Infections. , 2018, Journal of medicinal chemistry.

[24]  J. Lopez-Ribot,et al.  Development of Anti-Virulence Approaches for Candidiasis via a Novel Series of Small-Molecule Inhibitors of Candida albicans Filamentation , 2017, mBio.

[25]  D. Perlin,et al.  Fungal infections 5 The global problem of antifungal resistance: prevalence, mechanisms, and management , 2017 .

[26]  Felix Bongomin,et al.  Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision , 2017, Journal of fungi.

[27]  P. Chandrasekar,et al.  Candida auris: a worrisome, globally emerging pathogen , 2017, Expert review of anti-infective therapy.

[28]  M. Tashiro,et al.  In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen , 2017, The Journal of antimicrobial chemotherapy.

[29]  J. Perfect The antifungal pipeline: a reality check , 2017, Nature Reviews Drug Discovery.

[30]  A. Chowdhary,et al.  Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally , 2017, PLoS pathogens.

[31]  Michael Otto,et al.  Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance , 2017, Nature Reviews Drug Discovery.

[32]  J. Zhao,et al.  Synthesis and Biological Evaluation of Novel 2‐Aminonicotinamide Derivatives as Antifungal Agents , 2017, ChemMedChem.

[33]  J. Berman,et al.  Multidrug-Resistant Candida haemulonii and C. auris, Tel Aviv, Israel , 2017, Emerging infectious diseases.

[34]  Shanchao Wu,et al.  Tackling Fungal Resistance by Biofilm Inhibitors. , 2017, Journal of medicinal chemistry.

[35]  M. Slater,et al.  F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase , 2016, Proceedings of the National Academy of Sciences.

[36]  S. Brunke,et al.  Virulence factors in fungal pathogens of man. , 2016, Current opinion in microbiology.

[37]  Wannian Zhang,et al.  Strategies in the discovery of novel antifungal scaffolds. , 2016, Future medicinal chemistry.

[38]  S. Schuierer,et al.  Advantages and Challenges of Phenotypic Screens , 2016, Journal of biomolecular screening.

[39]  Shengzheng Wang,et al.  Meeting Organocatalysis with Drug Discovery: Asymmetric Synthesis of 3,3'-Spirooxindoles Fused with Tetrahydrothiopyrans as Novel p53-MDM2 Inhibitors. , 2016, Organic letters.

[40]  T. Kinoshita,et al.  Biosynthesis of GPI-anchored proteins: special emphasis on GPI lipid remodeling , 2016, Journal of Lipid Research.

[41]  David W. Denning,et al.  How to bolster the antifungal pipeline , 2015, Science.

[42]  C. Boone,et al.  Chemical Genomics-Based Antifungal Drug Discovery: Targeting Glycosylphosphatidylinositol (GPI) Precursor Biosynthesis , 2014, ACS infectious diseases.

[43]  Xiaomeng He,et al.  Novel carboline derivatives as potent antifungal lead compounds: design, synthesis, and biological evaluation. , 2014, ACS medicinal chemistry letters.

[44]  Benjamin J Park,et al.  Invasive Fungal Infections after Natural Disasters , 2014, Emerging infectious diseases.

[45]  E. Mylonakis,et al.  In Vitro and In Vivo Activities of Pterostilbene against Candida albicans Biofilms , 2014, Antimicrobial Agents and Chemotherapy.

[46]  G. Gu,et al.  Recent progress in synthetic and biological studies of GPI anchors and GPI-anchored proteins. , 2013, Current opinion in chemical biology.

[47]  N. Gow,et al.  Differential Virulence of Candida glabrata Glycosylation Mutants , 2013, The Journal of Biological Chemistry.

[48]  David W. Denning,et al.  Hidden Killers: Human Fungal Infections , 2012, Science Translational Medicine.

[49]  O. King,et al.  Inhibiting GPI anchor biosynthesis in fungi stresses the endoplasmic reticulum and enhances immunogenicity. , 2012, ACS chemical biology.

[50]  Ronald N. Jones,et al.  Activities of E1210 and Comparator Agents Tested by CLSI and EUCAST Broth Microdilution Methods against Fusarium and Scedosporium Species Identified Using Molecular Methods , 2011, Antimicrobial Agents and Chemotherapy.

[51]  Pravin Kumar,et al.  The Candida albicans homologue of PIG-P, CaGpi19p: gene dosage and role in growth and filamentation. , 2010, Microbiology.

[52]  N. Gow,et al.  Contribution of Candida albicans Cell Wall Components to Recognition by and Escape from Murine Macrophages , 2010, Infection and Immunity.

[53]  H. Korting,et al.  Targeting virulence: a new paradigm for antifungals. , 2009, Drug discovery today.

[54]  H. Yamaguchi,et al.  Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital , 2009, Microbiology and immunology.

[55]  S. Free,et al.  The structure and synthesis of the fungal cell wall , 2006, BioEssays : news and reviews in molecular, cellular and developmental biology.

[56]  T. Nagasu,et al.  Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly , 2003, Molecular microbiology.

[57]  G. Ruiz,et al.  What do we know about the biology of the emerging fungal pathogen of humans , 2020 .

[58]  M. Bassetti,et al.  What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead , 2018, The Journal of antimicrobial chemotherapy.

[59]  D. Enoch,et al.  The Changing Epidemiology of Invasive Fungal Infections. , 2017, Methods in molecular biology.

[60]  K. Hellingwerf,et al.  Molecular organization of the cell wall of Candida albicans. , 2001, Medical mycology.